PDB73 - INDIRECT COST-EFFECTIVENESS ANALYSIS OF EMPAGLIFLOZIN COMPARED TO CANAGLIFLOZIN FOR PATIENTS WITH T2DM AND CARDIOVASCULAR DISEASE IN THE SPANISH NATIONAL HEALTH SERVICE
Oct 1, 2018, 00:00
10.1016/j.jval.2018.09.778
https://www.valueinhealthjournal.com/article/S1098-3015(18)34078-6/fulltext
Title :
PDB73 - INDIRECT COST-EFFECTIVENESS ANALYSIS OF EMPAGLIFLOZIN COMPARED TO CANAGLIFLOZIN FOR PATIENTS WITH T2DM AND CARDIOVASCULAR DISEASE IN THE SPANISH NATIONAL HEALTH SERVICE
Citation :
https://www.valueinhealthjournal.com/action/showCitFormats?pii=S1098-3015(18)34078-6&doi=10.1016/j.jval.2018.09.778
First page :
Section Title :
Open access? :
No
Section Order :
180